As expected the Scottish Medicines Consortium quickly rejected eculizumab for aHUS under its non orphan DRUG process, and called for a PACE meeting to look at it.
This is due to be held on Tuesday 8 December in Glasgow.
Two trustees from aHUSUK will be representing Scottish aHUS patients at the meeting.
With the evidence gathered from that meeting from patient representatives and clinicians, the SMC will then decide some time in the new year ( click here for scheduled dates)on the policy to be recommended for all patients who need eculizumab for aHUS for as long as they need it in Scotland.
It will either be the final piece in the jigsaw of aHUS and eculizumab in the UK ( or not).